November 12, 2026 1:06 PM 3 min read
FDA Reportedly Shelves Fast-Track Drug Review Pilot Program During Leadership Vacuum: Report
The U.S. Food and Drug Administration (FDA) has reportedly halted its controversial fast-track drug review pilot program amid internal turmoil and a prolonged leadership vacuum.
The program was launched in June 2025 to shorten the review time from approximately 10-12 months to 1-2 months following a sponsor’s final drug application submission.
Citing six sources and internal records, Reuters on Thursday reported that the Commissioner’s National Priority Voucher program has stalled since former agency head Marty Makary exited in May.
Regulators once promoted the initiative as an aggressive reform for U.S. pharmaceutical oversight, yet infighting has left the effort adrift.
In November 2025, U.S. Rep. Frank Pallone and Sen. Bernie Sanders highlighted that the initiative was opaque.…